Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics.
Anji Pharmaceuticals has raised $70.0M in total funding. The most recent round was Series B. The last funding was announced in September 2021.
Anji Pharmaceuticals's investors include Kaitai Capital, JMCR Partners, Viva Ventures Biotech Fund, Viva BioInnovator, Xiamen Changrong Investment Management.
Anji Pharmaceuticals is headquartered in Cambridge, United States.
Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics.
Anji Pharmaceuticals is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Anji Pharmaceuticals — Funding & Investors." VCBacked, September 28, 2021, https://www.vcbacked.co/company/anji-pharmaceuticals. Accessed November 15, 2026.
VCBacked. (2021). Anji Pharmaceuticals — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/anji-pharmaceuticals
{{cite web |title=Anji Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/anji-pharmaceuticals |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Anji Pharmaceuticals? Request a listing update